Aktiesnakken — August 2010
-
ja og der er noget interessant imellem må man sige.
-
On my part, I could be wrong but I am willing to bet FCO + O maintenance will be an improvement on FCR.
-
I am also willing to bet fewer patients will develop hypersensitivity reactions ofatumamab – as my husband did to Rituxan
-
Dr. Michael Keating made some positive statements about FCO during one of our past visits.
-
Og for de uinvidede står o for ofatumumab og r for rituxian
-
og så siger jeg godnat derude
-
og fra en anden kommentar: Single agent O is better than single agent R.
-
Godnat!
-
god morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind